A phase Ib/II dose expansion study of subcutaneous sasanlimab in patients with locally advanced or metastatic non-small-cell lung cancer and urothelial carcinoma
Related Posts
Valle LF, Chu FI, Wang X, Erman A, Hernandez J, Kaoh E, Edgar N, Raldow AC, Wong DJ, Steinberg ML, Kishan AU, Chin RK, Hegde[...]
Cardoso F, O'Shaughnessy J, Liu Z, McArthur H, Schmid P, Cortes J, Harbeck N, Telli ML, Cescon DW, Fasching PA, Shao Z, Loirat D, Park[...]
Khan SH, Choi Y, Veena M, Lee JK, Shin DS. Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors.[...]